Cidara Therapeutics (CDTX) AI Stock Analysis

• Market Cap: $639.80M
• Dividend Yield: N/A
• Average Volume (3M): 643.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: -99.35%
• EPS Growth: -260.33%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -1.66
• Shares Outstanding: 12,969,823
• 10 Day Avg. Volume: 1,525,477
• 30 Day Avg. Volume: 643,050
• PEG Ratio: 0.04
• Price to Book (P/B): -18.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 0.29
• Enterprise Value/Gross Profit: 87.48
• Enterprise Value/Ebitda: -0.08
• 1Y Price Target: $57.00
• Price Target Upside: 15.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 56 Neutral
• Price Target: $51.00 ▲(3.13%Upside)

The overall score is driven by severe financial challenges that significantly impact Cidara Therapeutics' sustainability, despite strong technical momentum and positive corporate developments. Financial instability remains the most critical factor, outweighing recent positive trial results and financing efforts.

Positive Factors

Clinical Trial Success

CDTX announced positive topline results from the CD388 Ph2b Flu trial, with each dose level hitting statistical significance.

Market Opportunity

CD388 has potential for peak sales exceeding $1.5 billion in the U.S. for immunocompromised patients, based on estimates.

Regulatory Progress

The results likely allow CDTX to use the Ph2b trial as one of two well-controlled pivotal trials needed for registration, as guided by the FDA.

Negative Factors

Investor Uncertainty

Investor questions were focused on the CD388 Flu program, indicating potential uncertainty and need for more clarity on the company's initiatives.

Regulatory and Trial Risks

The company's recent regulatory discussions with the FDA could signal important updates and potential changes to the trial's statistical analysis plan.

Cidara Therapeutics Business Overview & Revenue Model

Company Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

How the Company Makes Money

Cidara Therapeutics generates revenue through a combination of product sales, collaborations, and licensing agreements. The company's revenue model is heavily dependent on its ability to advance its product candidates through clinical development and achieve market approval. Key revenue streams include milestone payments and royalties from licensing agreements with larger pharmaceutical companies, as well as government grants and funding for research and development. Strategic partnerships with other biotech and pharmaceutical firms significantly contribute to its earnings by providing both financial resources and access to complementary technologies.

Cidara Therapeutics Financial Statement Overview

Summary

Cidara Therapeutics faces significant financial challenges with persistent losses and negative cash flows. The balance sheet shows low leverage, but the company relies heavily on external financing. The biotechnology industry requires long-term investment before profitability, yet the current financial trajectory suggests a need for strategic improvements.

Income Statement

Cidara Therapeutics has experienced a significant revenue decline in the latest year, with a revenue growth rate of -98% from the previous year. The net profit margin is deeply negative, at -13362.04% for 2024, indicating substantial losses relative to revenue. The gross profit margin is also negative, suggesting that the company is selling below cost. While biotechnology companies often face high R&D expenses, the magnitude of losses is concerning.

Balance Sheet

The company's debt-to-equity ratio is low due to a relatively high stockholders' equity, indicating low leverage. However, the equity ratio is 76.02%, reflecting a stable capital structure. Despite this, the company has historically negative equity, raising concerns about sustainable financial health. The increase in cash reserves provides some liquidity cushion.

Cash Flow

Operating cash flow is significantly negative, although there has been substantial cash inflow from financing activities. Free cash flow remains negative, and the operating cash flow to net income ratio is negative, due to both operating cash flow and net income being negative. The company is heavily dependent on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	302.00K	1.27M	63.91M	64.29M	49.57M	12.07M
Gross Profit	245.00K	1.04M	62.38M	64.14M	49.38M	-55.95M
EBITDA	-107.74M	-176.10M	-24.36M	-33.36M	-42.26M	-71.56M
Net Income	-180.73M	-169.83M	-22.93M	-29.80M	-43.91M	-72.37M
Balance Sheet
Total Assets	191.73M	214.80M	67.03M	47.59M	75.33M	60.42M
Cash, Cash Equivalents and Short-Term Investments	168.15M	189.82M	35.78M	32.73M	62.27M	35.91M
Total Debt	2.67M	3.58M	4.88M	1.32M	5.06M	7.96M
Total Liabilities	50.05M	51.49M	75.24M	50.50M	53.75M	49.71M
Stockholders Equity	141.68M	163.31M	-8.21M	-2.90M	21.57M	10.71M
Cash Flow
Free Cash Flow	-191.94M	-176.66M	-22.94M	-28.59M	-25.27M	-54.60M
Operating Cash Flow	-191.84M	-176.53M	-22.43M	-28.47M	-25.23M	-54.41M
Investing Cash Flow	79.00K	-129.00K	-505.00K	-118.00K	-41.00K	-186.00K
Financing Cash Flow	337.23M	337.06M	25.98M	-951.00K	44.60M	37.28M

Cidara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDTX, the sentiment is Positive. The current price of 49.45 is above the 20-day moving average (MA) of 28.18, above the 50-day MA of 24.30, and above the 200-day MA of 19.73, indicating a bullish trend. The MACD of 5.46 indicates Negative momentum. The RSI at 81.64 is Negative, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CDTX.

Cidara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDTX	56 Neutral	$639.80M	―	-299.58%	―	-99.35%	-260.33%
OCGN	54 Neutral	$303.71M	―	-248.97%	―	86.63%	22.29%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
FHTX	49 Neutral	$273.13M	―	322.49%	―	-30.66%	36.48%
CRVS	41 Neutral	$317.71M	―	-100.13%	―	―	-71.53%
ITOS	41 Neutral	$384.27M	―	-23.68%	―	―	14.60%
TVGN	33 Underperform	$215.80M	―	-124.74%	―	―	-20.39%

Cidara Therapeutics Corporate Events

Cidara Therapeutics Announces $350 Million Stock Offering

On June 24, 2025, Cidara Therapeutics announced an agreement with several underwriters to sell approximately 7.95 million shares of its common stock at $44.00 per share in a public offering, aiming to raise around $350 million. The offering, scheduled to close on June 26, 2025, marks a significant financial move for Cidara, potentially enhancing its market position and providing capital to advance its therapeutic developments.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Cidara Therapeutics Suspends ATM Prospectus with Jefferies

On June 24, 2025, Cidara Therapeutics announced the suspension and termination of its ATM Prospectus related to common stock sales under its agreement with Jefferies LLC. The company will halt stock sales until a new prospectus is filed, though the sales agreement itself remains active, indicating a strategic pause rather than a complete cessation of stock activities.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Cidara Therapeutics Reports Positive Phase 2b Trial Results

On June 23, 2025, Cidara Therapeutics announced positive results from its Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. The trial demonstrated statistically significant prevention efficacy across all dose groups, with CD388 being well-tolerated and showing no unexpected adverse events. These results could enhance Cidara’s positioning in the antiviral market, and the company has submitted a meeting request to the FDA to discuss the Phase 3 trial design.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Cidara Therapeutics Approves Key Amendments at Annual Meeting

On June 18, 2025, Cidara Therapeutics held its Annual Meeting of Stockholders, where key amendments were approved. The stockholders agreed to increase the number of shares authorized under the 2024 Equity Incentive Plan by 2,880,000 shares and doubled the authorized shares of common stock from 50 million to 100 million. These changes are expected to enhance the company’s operational flexibility and support its growth strategy. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.